Literature DB >> 23888891

Expression of p21ras-related protein in the plasma and tissue of patients with adenomas and carcinomas of the colon.

J C Luo1, A I Neugut, G Garbowski, K A Forde, M Treat, S Smith, H Niman, P W Brandt-Rauf.   

Abstract

Abstract Over-expression of p21 ras-related protein was determined in the plasma by immunoblotting and in the tissue by immuno-histochemistry in a cohort of patients undergoing colonoscopy. In the plasma samples, p21 ras over-expression was detected in: 9% (4/47) of normal controls; 21% (13/61) of individuals with normal colonoscopies but with a prior history of colonic neoplasia; 12% (4/33) of small adenoma patients, 29% (6/21) of large adenoma patients; 63% (5/8) of carcinoma-in-adenoma patients; 50% (2/4) of Dukes' A carcinoma patients; and 20% (2/10) of Dukes' B-D carcinoma patients. In the tissue samples, p21 ras over-expression was detected in: 25% (2/8) of small adenoma patients; 44% (4/9) of large adenoma patients; 100% (4/4) of carcinoma-in-adenoma patients; and 33% (1/3) of Dukes' B-C carcinoma patients. For matched plasma-tissue pairs, there was a statistically significant correlation for p21 ras over-expression (R = 0.47, p = 0.02).

Entities:  

Year:  1996        PMID: 23888891     DOI: 10.3109/13547509609079344

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  2 in total

1.  Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

Authors:  P W Brandt-Rauf; J M Chen; M J Marion; S J Smith; J C Luo; W Carney; M R Pincus
Journal:  J Protein Chem       Date:  1996-05

2.  Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Authors:  Malgorzata Banys-Paluchowski; Tanja Fehm; Wolfgang Janni; Bahriye Aktas; Peter A Fasching; Sabine Kasimir-Bauer; Karin Milde-Langosch; Klaus Pantel; Brigitte Rack; Sabine Riethdorf; Erich-Franz Solomayer; Isabell Witzel; Volkmar Müller
Journal:  BMC Cancer       Date:  2018-05-08       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.